Skip to main content
ATEC
NASDAQ Industrial Applications And Services

ATEC Q2 Revenue Climbs 15%, EBITDA Outlook Raised as Profitability Turns

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$9.83
Mkt Cap
$1.592B
52W Low
$6.82
52W High
$23.29
52W Position info
44% above low
Off High info
58% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

ATEC sits 44% above its 52-week low of $6.82.

Summary

Alphatec reported Q2 revenue of $214M (+15% YoY) with non-GAAP net income of $11M and raised its full-year adjusted EBITDA guidance to ~$140M, signaling improving profitability and cash generation.


Key Events · Earnings and Guidance · ATEC

  • Q2 Revenue and Volume Growth

    Total revenue reached $214M, up 15% year-over-year, driven by surgical revenue of $196M (+17%) on 20% case volume growth and a 24% increase in net new surgeon users.

  • Profitability Inflection

    Non-GAAP net income hit $11M versus $2.6M a year ago; adjusted EBITDA of $36M (16.8% margin) expanded 420 bps YoY, and the company generated positive free cash flow in the quarter.

  • Raised EBITDA Guidance

    Full-year 2026 adjusted EBITDA guidance was raised to ~$140M from ~$134M, while the revenue outlook of ~$882M (including ~$805M surgical) was reaffirmed; free cash flow is expected to be at least $20M.

  • GAAP Loss Reflects Non-Cash Charges

    GAAP net loss of ($26)M included an $11.9M loss on debt extinguishment and $6.6M in non-cash interest expense; the operating loss narrowed to ($1.9)M from ($13.1)M a year ago.


Analysis · ATEC · Industrial Applications And Services

Alphatec delivered a strong Q2, with surgical revenue up 17% on 20% case volume growth, and non-GAAP net income swung to a positive $11M from a loss a year ago. Adjusted EBITDA reached $36M—a 16.8% margin—expanding 420 bps year-over-year, while the company generated positive free cash flow. Management raised full-year adjusted EBITDA guidance to ~$140M from ~$134M and reaffirmed the ~$882M revenue target. The results show the spine-focused medtech is approaching sustainable profitability, though GAAP net loss remains at ($26)M due to non-cash charges including an $11.9M debt extinguishment loss. The balance sheet carries $119M in cash against $65M short-term debt, and the recent refinancing reduces the interest burden. This earnings print confirms the operational turnaround narrative and supports the stock's recent insider accumulation signal.

At the time of this filing, ATEC was trading at $9.83 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $6.82 to $23.29. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ATEC - Latest Insights

ATEC
Aug 04, 2026, 4:57 PM EDT
Filing Type: 10-Q
Importance Score:
7
ATEC
Jun 11, 2026, 4:13 PM EDT
Filing Type: 8-K
Importance Score:
8
ATEC
May 06, 2026, 1:02 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
ATEC
May 05, 2026, 4:56 PM EDT
Filing Type: 10-Q
Importance Score:
8
ATEC
May 05, 2026, 4:35 PM EDT
Source: Reuters
Importance Score:
8